Terms: = Bone cancer AND IKZF1, LyF-1, 10320, ENSG00000185811, Q13422, Hs_54452, hIk-1, ZNFN1A1, IKAROS AND Treatment
22 results:
1. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
[TBL] [Abstract] [Full Text] [Related]
2. Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.
Bastian L; Beder T; Barz MJ; Bendig S; Bartsch L; Walter W; Wolgast N; Brändl B; Rohrandt C; Hansen BT; Hartmann AM; Iben K; Das Gupta D; Denker M; Zimmermann J; Wittig M; Chitadze G; Neumann M; Schneller F; Fiedler W; Steffen B; Stelljes M; Faul C; Schwartz S; Müller FJ; Cario G; Harder L; Haferlach C; Pfeifer H; Gökbuget N; Brüggemann M; Baldus CD
Blood; 2024 Apr; 143(14):1391-1398. PubMed ID: 38153913
[TBL] [Abstract] [Full Text] [Related]
3. [Clinical characteristics and therapeutic effect of TP53 variant in patients with acute leukemia].
Mi R; Guo Z; Liu W; Hu J; Fan R; Chen L; Liu J; Wei X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2021 Oct; 38(10):955-960. PubMed ID: 34625931
[TBL] [Abstract] [Full Text] [Related]
4. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
Ishibashi M; Yamamoto J; Ito T; Handa H; Sunakawa-Kii M; Inokuchi K; Morita R; Tamura H
Mol Cancer Ther; 2021 Jul; 20(7):1283-1294. PubMed ID: 33879556
[TBL] [Abstract] [Full Text] [Related]
5. The ikzf1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.
Mougiakakos D; Bach C; Böttcher M; Beier F; Röhner L; Stoll A; Rehli M; Gebhard C; Lischer C; Eberhardt M; Vera J; Büttner-Herold M; Bitterer K; Balzer H; Leffler M; Jitschin S; Hundemer M; Awwad MHS; Busch M; Stenger S; Völkl S; Schütz C; Krönke J; Mackensen A; Bruns H
Cancer Immunol Res; 2021 Mar; 9(3):265-278. PubMed ID: 33563611
[TBL] [Abstract] [Full Text] [Related]
6. Frequency and Correlation of Common Genes Copy Number Alterations in Childhood Acute Lymphoblastic Leukemia with Prognosis.
Hosein Pour Feizi A; Zeinali S; Toporski J; Sheervalilou R; Mehranfar S
Asian Pac J Cancer Prev; 2020 Dec; 21(12):3493-3500. PubMed ID: 33369444
[TBL] [Abstract] [Full Text] [Related]
7. Antimyeloma Potential of Caffeic Acid Phenethyl Ester and Its Analogues through Sp1 Mediated Downregulation of ikzf1-IRF4-MYC Axis.
Murugesan A; Lassalle-Claux G; Hogan L; Vaillancourt E; Selka A; Luiker K; Kim MJ; Touaibia M; Reiman T
J Nat Prod; 2020 Dec; 83(12):3526-3535. PubMed ID: 33210536
[TBL] [Abstract] [Full Text] [Related]
8. Old and new generation immunomodulatory drugs in multiple myeloma.
Derudas D; Capraro F; Martinelli G; Cerchione C
Panminerva Med; 2020 Dec; 62(4):207-219. PubMed ID: 32955182
[TBL] [Abstract] [Full Text] [Related]
9. Myeloma Cells Are Activated in bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide.
Kikuchi J; Kuroda Y; Koyama D; Osada N; Izumi T; Yasui H; Kawase T; Ichinohe T; Furukawa Y
Cancer Res; 2018 Apr; 78(7):1766-1778. PubMed ID: 29363546
[TBL] [Abstract] [Full Text] [Related]
10. Plant homeodomain finger protein 2 as a novel ikaros target in acute lymphoblastic leukemia.
Ge Z; Gu Y; Han Q; Sloane J; Ge Q; Gao G; Ma J; Song H; Hu J; Chen B; Dovat S; Song C
Epigenomics; 2018 Jan; 10(1):59-69. PubMed ID: 28994305
[TBL] [Abstract] [Full Text] [Related]
11. Genomic analysis of adult B-ALL identifies potential markers of shorter survival.
Patel S; Mason CC; Glenn MJ; Paxton CN; South ST; Cessna MH; Asch J; Cobain EF; Bixby DL; Smith LB; Reshmi S; Gastier-Foster JM; Schiffman JD; Miles RR
Leuk Res; 2017 May; 56():44-51. PubMed ID: 28193567
[TBL] [Abstract] [Full Text] [Related]
12. ikaros expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
Bolomsky A; Hübl W; Spada S; Müldür E; Schlangen K; Heintel D; Rocci A; Weißmann A; Fritz V; Willheim M; Zojer N; Palumbo A; Ludwig H
Am J Hematol; 2017 Mar; 92(3):269-278. PubMed ID: 28052520
[TBL] [Abstract] [Full Text] [Related]
13. Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia.
Vesely C; Frech C; Eckert C; Cario G; Mecklenbräuker A; Zur Stadt U; Nebral K; Kraler F; Fischer S; Attarbaschi A; Schuster M; Bock C; Cavé H; von Stackelberg A; Schrappe M; Horstmann MA; Mann G; Haas OA; Panzer-Grümayer R
Leukemia; 2017 Jul; 31(7):1491-1501. PubMed ID: 27899802
[TBL] [Abstract] [Full Text] [Related]
14. Co-existence of IL7R high and SH2B3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with ikaros dysfunction.
Ge Z; Gu Y; Xiao L; Han Q; Li J; Chen B; Yu J; Kawasawa YI; Payne KJ; Dovat S; Song C
Oncotarget; 2016 Jul; 7(29):46014-46027. PubMed ID: 27322554
[TBL] [Abstract] [Full Text] [Related]
15. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.
Fang J; Liu X; Bolanos L; Barker B; Rigolino C; Cortelezzi A; Oliva EN; Cuzzola M; Grimes HL; Fontanillo C; Komurov K; MacBeth K; Starczynowski DT
Nat Med; 2016 Jul; 22(7):727-34. PubMed ID: 27294874
[TBL] [Abstract] [Full Text] [Related]
16. Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia.
Griffith M; Griffith OL; Krysiak K; Skidmore ZL; Christopher MJ; Klco JM; Ramu A; Lamprecht TL; Wagner AH; Campbell KM; Lesurf R; Hundal J; Zhang J; Spies NC; Ainscough BJ; Larson DE; Heath SE; Fronick C; O'Laughlin S; Fulton RS; Magrini V; McGrath S; Smith SM; Miller CA; Maher CA; Payton JE; Walker JR; Eldred JM; Walter MJ; Link DC; Graubert TA; Westervelt P; Kulkarni S; DiPersio JF; Mardis ER; Wilson RK; Ley TJ
Exp Hematol; 2016 Jul; 44(7):603-13. PubMed ID: 27181063
[TBL] [Abstract] [Full Text] [Related]
17. Differential effects of lenalidomide during plasma cell differentiation.
Jourdan M; Cren M; Schafer P; Robert N; Duperray C; Vincent L; Ceballos P; Cartron G; Rossi JF; Moreaux J; Chopra R; Klein B
Oncotarget; 2016 May; 7(19):28096-111. PubMed ID: 27057635
[TBL] [Abstract] [Full Text] [Related]
18. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
Sutton R; Shaw PJ; Venn NC; Law T; Dissanayake A; Kilo T; Haber M; Norris MD; Fraser C; Alvaro F; Revesz T; Trahair TN; Dalla-Pozza L; Marshall GM; O'Brien TA
Br J Haematol; 2015 Feb; 168(3):395-404. PubMed ID: 25312094
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.
Krentz S; Hof J; Mendioroz A; Vaggopoulou R; Dörge P; Lottaz C; Engelmann JC; Groeneveld TW; Körner G; Seeger K; Hagemeier C; Henze G; Eckert C; von Stackelberg A; Kirschner-Schwabe R
Leukemia; 2013 Feb; 27(2):295-304. PubMed ID: 22699455
[TBL] [Abstract] [Full Text] [Related]
20. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.
Passamonti F; Maffioli M; Caramazza D; Cazzola M
Oncotarget; 2011 Jun; 2(6):485-90. PubMed ID: 21646683
[TBL] [Abstract] [Full Text] [Related]
[Next]
